ArticleCancers2022

Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial.

Markus Diefenhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.